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1. Introduction 
Many short-term responses to extra-cellular stimuli 
are apparently mediated by changes in the content of 
cyclic-AMP in cells [I] . However, a group of hor- 
mones can exert a rapid catabolic effect on liver 
glycogen metabolism, which is not mediated by cyclic- 
AMP, and does not involve activation of cyclic-AMP- 
dependent protein kinase [2]. This was first demon- 
strated by a study of cY-adrenergic mechanisms [3] 
and the lack of a role for cyclic-AMP in cu-adrenergic 
effects has consistently emerged in subsequent 
investigations [4-71. A further hormone which 
stimulates glycogen breakdown is vasopressin [8] 
which also causes no increase in hepatic ontent of 
cyclic-AMP [9]. Both vasopressin and angiotensin II 
can increase the amount of available glycogen phos- 
phorylase uin liver [ IO,1 I] but without associated 
activation of assayable protein kinase or phosphorylase 
kinase [ll]. 
The above hormones can exert catabolic effects on 
lipid metabolism [2] and on other processes in liver, 
so it is important o gain further insight into their 
mechanism of action and their effects on nucleotide 
levels in liver. As angiotensin II does not produce a 
stable activation of phosphorylase kinase in liver [ 1 l] 
it should follow that this hormone does not increase 
liver cyclic-AMP content. Also, oxytocin, which can 
inhibit hepatic glycogen synthesis [ 121, would be 
expected to act on the same receptor as vasopressin 
and, therefore, not to alter the cyclic-AMP content. 
These predictions are confirmed here. 
Another purine nucleoside cyclic monophosphate 
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which may be implicated in hormone response 
mechanisms is cyclic-GMP. The effects of the above- 
described hormones on the contents of cyclic-AMP 
and cyclic-GMP in perfused rat liver are described 
here. They were determined by radioimmunoassay, 
which offers the most specific and precise method for 
analysis of these nucleotides. T’he contents of these 
cyclic nucleotides in livers perfused with insulin and 
acetyl choline are also reported. 
2. Experimental 
Livers of fed male 200 g Sprague-Dawley rats were 
perfused with Krebs-Ringer-bicarbonate saline con- 
taining rat erythrocytes (haematocrit 12%) bovine 
serum albumin (2.5% w/v), and glucose which 
remained steady at about 10 mM [8] . After 40 min, 
hormones were added as a single dose; after a further 
short period, livers were rapidly freeze-clamped. 
Effluent perfusate was sampled over about 30 s, with 
a mean point at 5 min or 10 min after hormone 
addition; cells were immediately deposited by brief 
centrifugation and plasma was removed. 
Tissue samples were extracted with 10 vol. 10% 
trichloroacetic acid (TCA) and plasma samples with 
equal vol. TCA. Precipitated protein was removed by 
centrifugation. Extracts were stored frozen for not 
more than 10 days before analysis of purine nucleoside 
cyclic monophosphates by radioimmunoassay 
[13-151. 
Extracts were washed with water-saturated diethyl 
ether to remove the TCA. Cyclic-AMP was measured 
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directly in these extracts as in [ 141. Cyclic-GMP in 
extracts was concentrated 5-fold and purified before 
assay, by elution from a column of AC l-X2 resin, 
Cl- form, with 300 mM HCl, as in [ 151. Standard 
curves were constructed using pure nucleotides in 
amounts from 10-13-10-” mol in the assay. Standard 
amounts of nucleotides added to extracts were 
recovered quantitatively (90-l 10%). Treatment of 
extracts with beef heart phosphodiesterase (Boehringer 
Corp. Ltd.) destroyed all exogenous cyclic nucleotides 
added and more than 85% of endogenous immuno- 
reactive material in both assays. The residual activity 
detected after phosphodiesterase tr atment was near 
the lower limits of the assay procedures. 
3. Results and discussion 
The hepatic contents of cyclic-AMP and cyclic- 
GMP, in response to various hormones, are given in 
table 1. The values in control liver and perfusate are 
of the same order as those reported in other studies. 
Perfusate cyclic nucleotide concentrations were 
measured as these should provide a sensitive index of 
small changes in tissue content [ 161. In agreement 
with this expectation, glucagon produced an approx. 
lo-fold increase in tissue cyclic-AMP content but a 
loo-fold rise in the concentration i  perfusate. 
Further hormones were investigated which exert a 
glycogenolytic effect on liver at the concentrations 
employed in these perfusions [8- 131. Vasopressin 
did not increase cyclic-AMP in liver or perfusate, 
confirming previous measurements [9], and it also 
did not affect cyclic-GMP. Angiotensin II and oxy- 
tocin did not alter the concentration of cyclic-AMP 
or cyclic-GMP in liver or perfusate (table 1). 
Of the two agents tested which can exert anabolic 
effects on liver metabolism, neither insulin nor acetyl 
choline brought about any change in the cyclic-AMP 
or cyclic-GMP content of liver or perfusate. This 
contrasts with their reported action on liver slices [171 .
Although these findings are in one sense negative, 
they offer a powerful insight into the mechanisms of 
action on liver of the above hormones (other than 
glucagon); thus the data show that none of the mul- 
tiple effects which these hormones exert on liver can 
be mediated by either purine nucleoside cyclic mono- 
phosphate. 
The group of hormones which can exert catabolic 
effects on liver metabolism, not mediated by cyclic- 
AMP or cyclic-GMP, currently comprises catechol- 
amines (a-adrenergic mechanism [3-7]), vasopressin, 
oxytocin and angiotensin II. Their mechanism of
action may involve Ca2+ [2,4,6,11,18-201 but details 
still have to be clarified. 
Table 1 
Contents of purine nucleoside cyclic monophosphates in perfused liver 
Hormone Min after Content of nucleotide 
Hormone 
Liver (pmol/g) Plasma (nM) 
- -~ 
Cyclic AMP Cyclic GMP Cyclic AMP ‘Cyclic GMP 
Control _ 890 + 70(B) 23 f 3 (9) 8.6 f 2.3 (9) 1.0 f 0.2 (7) 
Glucagon (lo-’ M) 10 8500 * 380 (3) 13*3(3) 880 f 370 (3) 1.3 * 0.2 (3) 
Vasopressin (5 mu/ml) .lO 710+ 20(4) 17 f 2 (3) 7.8 f 2.7 (5) 0.8 + 0.2 (5) 
Oxytocin (1 U/ml) 5 940 + 30 (3) 18 ? 2 (3) 7.0 + 2.0 (3) 0.7 * 0.1 (3) 
Angiotensin II (4 ng/ml) 5 880 + SO(4) 24 f 4 (4) 5.0 * 2.0 (3) 0.6 f 0.1 (3) 
Acetyl choline (20 fig/ml) 10 780 + 50(S) 22 f 2 (5) 6.2 + 2.3 (5) 1.3 f 0.2 (4) 
Insulin (10 mu/ml) 10 710 * 20(5) 17 f 2 (5) 12.7 f 7.8 (3) 0.8 * 0.1 (3) 
Vasopressin (mU/ml)a 10 980 (2) - 1.5 (2) 0.9 (2) 
a Average values from two perfusions of mouse liver 
Livers from fed male Sprague-Dawley rats (200 g) were perfused, and at 40 min, hormones were added as a single dose. Control 
perfusions received no addition. Liver and perfusate plasma were analysed for cyclic-AMP and cyclic-GMP by radio immunoassay. 
Results are means t S.E.M. of the number of measurements in parentheses 
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